BioPharma Dive - Latest News

Merck bets $200M on a new type of heart pill

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a). 

Mar 25, 2025 - 17:12
 0
Merck bets $200M on a new type of heart pill

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a). 

Read More

Tags:

Previous Article

GBRX head promises ‘innovation with a purpose’ to tackle rail problems

Next Article

Human medicines European public assessment report (EPAR): Prasugrel Viatris (pre...

Related Posts

FTC case against PBMs can move forward, judge rules

FTC case against PBMs can move forward, judge rules

Feb 20, 2025  0

Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy

Amgen readies pivotal MariTide trials; Novo offers disc...

Mar 6, 2025  0

Federal judge extends block on Trump plan to limit NIH payouts

Federal judge extends block on Trump plan to limit NIH ...

Mar 6, 2025  0